MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with poor prognosis, which is characterised by destruction of normal lung architecture and excessive deposition of lung extracellular matrix. The heterogeneity of disease progression in patients with IPF poses significant obstacles to patient care and prevents efficient development of novel therapeutic interventions. Blood biomarkers, reflecting pathobiological processes in the lung, could provide objective evidence of the underlying disease. Longitudinally collected serum samples from the Bosentan Use in Interstitial Lung Disease (BUILD)-3 trial were used to measure four biomarkers (metalloproteinase-7 (MMP-7), Fas death receptor ligand, osteopontin and procollagen type I C-peptide), to assess their potential prognostic capabilities and to follow changes during disease progression in patients with IPF. In baseline BUILD-3 samples, only MMP-7 showed clearly elevated protein levels compared with samples from healthy controls, and further investigations demonstrated that MMP-7 levels also increased over time. Baseline levels of MMP-7 were able to predict patients who had higher risk of worsening and, notably, baseline levels of MMP-7 could predict changes in FVC as early as month 4. MMP-7 shows potential to be a reliable predictor of lung function decline and disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This ATX – LPA – LPA receptor axis has been found to play a role in the pathogenesis of IPF, and can decrease severity of bleomycin induced pulmonary fibrosis in mouse models [100].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [100]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Analysis of Transformations
Box, G. E. P., & Cox, D. R. (1964) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1964.tb00553.x · Cited by 15,052
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-10-201205150-00004 · Cited by 1,308
Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study
Coghlan, J. G., Denton, C. P., Grünig, E., Bonderman, D., Distler, O., Khanna, D., Müller-Ladner, U., Pope, J. E., Vonk, M. C., Doelberg, M., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203301 · Cited by 832
BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1874oc · Cited by 718
Self-citationMyocardial Fibrosis as an Early Manifestation of Hypertrophic Cardiomyopathy
Ho, C. Y., López, B., Coelho-Filho, O. R., Lakdawala, N. K., Cirino, A. L., Jarolim, P., Kwong, R., González, A., Colan, S. D., Seidman, J. G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002659 · Cited by 696
MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis
Rosas, I. O., Richards, T. J., Konishi, K., Zhang, Y., Gibson, K., Lokshin, A. E., Lindell, K. O., Cisneros, J., MacDonald, S. D., Pardo, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050093 · Cited by 588
(2007) · Clinical Atlas of Interstitial Lung Disease · doi:10.1007/978-1-84628-326-0_6 · Cited by 499
Up-Regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary Fibrosis
Pardo, A., Gibson, K., Cisneros, J., Richards, T. J., Yang, Y., Becerril, C., Yousem, S., Herrera, I., Ruiz, V., Selman, M., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020251 · Cited by 489
Cited by
Cardoso, A. L., Fernandes, A., Aguilar-Pimentel, J. A., de Angelis, M. H., Guedes, J. R., Brito, M. A., Ortolano, S., Pani, G., Athanasopoulou, S., Gonos, E. S., et al. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.07.004 · Cited by 475
Savin, I. A., Zenkova, M. A., & Sen’kova, A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314959 · Cited by 279
The natural history of progressive fibrosing interstitial lung diseases
Kolb, M., & Vašáková, M. (2019) · Respiratory Research · doi:10.1186/s12931-019-1022-1 · Cited by 269
Diagnostic Accuracy of Serum Matrix Metalloproteinase‐7 for Biliary Atresia
Li, Y., Zhou, Y., Xu, P., Mourya, R., Lei, H., Cao, G., Xiong, X., Xu, H., Duan, X., Wang, N., et al. (2018) · Hepatology · doi:10.1002/hep.30234 · Cited by 151
Biomarkers in idiopathic pulmonary fibrosis
Drakopanagiotakis, F., Wujak, L., Wygrecka, M., & Markart, P. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.023 · Cited by 132
Metadata
- Authors
- Bauer, Y., White, E. S., de Bernard, S., Cornelisse, P., Leconte, I., Morganti, A., Roux, S., & Nayler, O.
- Affiliations
- Actelion (Switzerland) (CH)
- University of Michigan (US)
- Corresponding author
- Bauer, Yasmina
- Venue
- ERJ Open Research
- Publisher
- European Respiratory Society (ERS)
- Published
- 2017-01
- Volume
- 3
- Issue
- 1
- Pages
- 00074-2016
- ISSN
- 2312-0541 (ISSN-L)
- PMC
- PMC5395293
- OpenAlex
- W2603140425
- Cited by
- 139
- References
- 36
- Citations by year
- 2026: 16 · 2025: 19 · 2024: 23 · 2023: 14 · 2022: 7 · 2021: 17 · 2020: 13 · 2019: 16 · 2018: 13 · 2017: 1
- FWCI
- 9.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- ERJ Open Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- NIH Office of the Director (R01 HL109118)
- Drews Sarcoidosis research fund
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, MMP-7, predictive biomarkers, disease progression, osteopontin, lung function decline, forced vital capacity, serum biomarkers, interstitial lung disease, bosentan
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1183/23120541.00074-2016
- The paper
- Bauer, Y., White, E. S., de Bernard, S., Cornelisse, P., Leconte, I., Morganti, A., Roux, S., & Nayler, O. (2017). MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis. ERJ Open Research. https://doi.org/10.1183/23120541.00074-2016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.